NYSE:OGN Organon & Co. (OGN) Stock Price, News & Analysis $8.82 -0.77 (-7.98%) As of 10:38 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Organon & Co. Stock (NYSE:OGN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Organon & Co. alerts:Sign Up Key Stats Today's Range$8.82▼$9.4150-Day Range$9.44▼$15.8152-Week Range$8.82▼$23.10Volume3.57 million shsAverage Volume4.06 million shsMarket Capitalization$2.29 billionP/E Ratio2.65Dividend Yield12.69%Price Target$19.67Consensus RatingHold Company OverviewOrganon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.Read More… Organon & Co. Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks95th Percentile Overall ScoreOGN MarketRank™: Organon & Co. scored higher than 95% of companies evaluated by MarketBeat, and ranked 61st out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus RatingOrganon & Co. has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 2 hold ratings, and 1 sell rating.Amount of Analyst CoverageOrganon & Co. has only been the subject of 3 research reports in the past 90 days.Read more about Organon & Co.'s stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth1.63% Earnings GrowthEarnings for Organon & Co. are expected to grow by 1.63% in the coming year, from $3.68 to $3.74 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Organon & Co. is 2.88, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 22.01.Price to Earnings Ratio vs. SectorThe P/E ratio of Organon & Co. is 2.88, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 22.81.Price to Earnings Growth RatioOrganon & Co. has a PEG Ratio of 0.90. PEG Ratios below 1 indicate that a company could be undervalued. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.78% of the float of Organon & Co. has been sold short.Short Interest Ratio / Days to CoverOrganon & Co. has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in Organon & Co. has recently increased by 15.20%, indicating that investor sentiment is decreasing significantly. Dividend3.3 / 5Dividend StrengthStrong Dividend LeadershipOrganon & Co. is a leading dividend payer. It pays a dividend yield of 8.81%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthOrganon & Co. does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Organon & Co. is 33.63%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Organon & Co. will have a dividend payout ratio of 29.95% next year. This indicates that Organon & Co. will be able to sustain or increase its dividend.Read more about Organon & Co.'s dividend. Sustainability and ESG3.7 / 5Environmental Score-2.37 Percentage of Shares Shorted6.78% of the float of Organon & Co. has been sold short.Short Interest Ratio / Days to CoverOrganon & Co. has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in Organon & Co. has recently increased by 15.20%, indicating that investor sentiment is decreasing significantly. News and Social Media3.2 / 5News Sentiment0.72 News SentimentOrganon & Co. has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 29 news articles for Organon & Co. this week, compared to 6 articles on an average week.Search Interest33 people have searched for OGN on MarketBeat in the last 30 days. This is an increase of 10% compared to the previous 30 days.MarketBeat Follows17 people have added Organon & Co. to their MarketBeat watchlist in the last 30 days. This is an increase of 143% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Organon & Co. insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.40% of the stock of Organon & Co. is held by insiders.Percentage Held by Institutions77.43% of the stock of Organon & Co. is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Organon & Co.'s insider trading history. Receive OGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Organon & Co. and its competitors with MarketBeat's FREE daily newsletter. Email Address OGN Stock News HeadlinesOGN INVESTIGATION ALERT: Investigation Launched into Organon & Co. ...May 5 at 7:23 AM | gurufocus.comOGN INVESTIGATION ALERT: Investigation Launched into Organon & Co. and Attorneys Encourage Investors with Substantial Losses or Witnesses with Relevant Information to Contact Law FirmMay 5 at 6:00 AM | prnewswire.comWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.May 5, 2025 | Altimetry (Ad)Organon & Co. Sees Unusually Large Options Volume (NYSE:OGN)May 3 at 2:56 AM | americanbankingnews.comOrganon & Co (OGN) Q1 2025 Earnings Call Highlights: Navigating Growth Amidst Revenue ChallengesMay 3 at 1:10 AM | finance.yahoo.comBrokerages Set Organon & Co. (NYSE:OGN) PT at $19.75May 3 at 1:09 AM | americanbankingnews.comOGN INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Announces Investigation into Organon & Co. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the FirmMay 2 at 6:37 PM | globenewswire.comWhy The Low Payout Ratio Did Not Stop The Dividend Cut For OrganonMay 2 at 10:12 AM | seekingalpha.comSee More Headlines OGN Stock Analysis - Frequently Asked Questions How have OGN shares performed this year? Organon & Co.'s stock was trading at $14.92 at the beginning of the year. Since then, OGN stock has decreased by 35.7% and is now trading at $9.60. View the best growth stocks for 2025 here. How were Organon & Co.'s earnings last quarter? Organon & Co. (NYSE:OGN) issued its earnings results on Thursday, May, 1st. The company reported $1.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.89 by $0.13. Organon & Co.'s revenue was down 6.7% compared to the same quarter last year. Read the conference call transcript. Who are Organon & Co.'s major shareholders? Top institutional shareholders of Organon & Co. include Massachusetts Financial Services Co. MA (4.12%), Bank of New York Mellon Corp (1.43%), Principal Financial Group Inc. (0.50%) and Cerity Partners LLC (0.44%). View institutional ownership trends. How do I buy shares of Organon & Co.? Shares of OGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Organon & Co. own? Based on aggregate information from My MarketBeat watchlists, some other companies that Organon & Co. investors own include Chevron (CVX), Bristol-Myers Squibb (BMY), McKesson (MCK), Comcast (CMCSA), Charles Schwab (SCHW), Edwards Lifesciences (EW) and Yum! Brands (YUM). Company Calendar Record date for 3/13 Dividend2/24/2025Ex-Dividend for 3/13 Dividend2/24/2025Dividend Payable3/13/2025Last Earnings5/01/2025Today5/05/2025Record date for 6/12 Dividend5/12/2025Ex-Dividend for 6/12 Dividend5/12/2025Dividend Payable6/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:OGN CIK1821825 Webwww.organon.com Phone551-430-6900FaxN/AEmployees10,000Year FoundedN/APrice Target and Rating Average Stock Price Target$19.67 High Stock Price Target$24.00 Low Stock Price Target$15.00 Potential Upside/Downside+104.9%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$3.33 Trailing P/E Ratio2.88 Forward P/E Ratio2.61 P/E Growth0.9Net Income$864 million Net Margins13.49% Pretax Margin12.60% Return on Equity431.62% Return on Assets8.03% Debt Debt-to-Equity Ratio17.73 Current Ratio1.70 Quick Ratio1.21 Sales & Book Value Annual Sales$6.40 billion Price / Sales0.39 Cash Flow$3.08 per share Price / Cash Flow3.12 Book Value($0.27) per share Price / Book-35.56Miscellaneous Outstanding Shares259,956,000Free Float253,933,000Market Cap$2.50 billion OptionableNot Optionable Beta0.73 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NYSE:OGN) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredU.S. Stock Market Now on Verge of CollapseThe last time the U.S. economy looked like this, stocks didn't move for 16 years... And many investors lost...Stansberry Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organon & Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Organon & Co. With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.